Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Sarah Cannon Research Institute Bristol-Myers Squibb |
---|---|
Information provided by: | Sarah Cannon Research Institute |
ClinicalTrials.gov Identifier: | NCT00193193 |
In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone refractory prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Paclitaxel Drug: Estramustine Drug: Carboplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma |
Estimated Enrollment: | 100 |
Study Start Date: | August 2000 |
Upon determination of eligibility, patients will receive:
Paclitaxel + Estramustine + Carboplatin
Patients will receive weekly paclitaxel and low-dose estramustine, in combination with carboplatin administered either weekly r every four weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
You cannot participate in this study if any of the following apply to you:
Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Study ID Numbers: | SCRI GU 10 |
Study First Received: | September 12, 2005 |
Last Updated: | October 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00193193 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents, Hormonal Estramustine Urogenital Neoplasms Antimitotic Agents Carboplatin Genital Diseases, Male |
Hormones Carcinoma Paclitaxel Tubulin Modulators Antineoplastic Agents, Alkylating Antineoplastic Agents, Phytogenic Prostatic Neoplasms Alkylating Agents |
Molecular Mechanisms of Pharmacological Action Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents, Hormonal Antineoplastic Agents Mitosis Modulators Estramustine Urogenital Neoplasms Antimitotic Agents Carboplatin Genital Diseases, Male |
Pharmacologic Actions Neoplasms Neoplasms by Site Paclitaxel Therapeutic Uses Tubulin Modulators Antineoplastic Agents, Alkylating Antineoplastic Agents, Phytogenic Alkylating Agents Prostatic Neoplasms |